East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Exemestane Tablets USP, 25 mg.  Aurobindo Pharma’s Exemestane Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN® tablets, manufactured by Pfizer Inc, USA.  

Exemestane Tablets are indicated for:

• Adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer.
• Treatment of advanced breast cancer in postmenopausal women, whose disease has progressed following tamoxifen therapy.